British journal of cancer

publication venue for

A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies.. 127. 2022
Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.. 127. 2022
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.. 126. 2022
Immune biomarkers and response to checkpoint inhibition of BRAF^V600 and BRAF non-V600 altered lung cancers.. 126. 2021
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.. 126. 2021
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.. 126. 2021
Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy.. 125. 2021
Mendelian randomisation study of smoking exposure in relation to breast cancer risk.. 125. 2021
Mammographic microcalcifications and risk of breast cancer.. 125. 2021
TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma.. 125. 2021
CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers.. 124. 2021
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.. 124. 2021
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.. 122. 2019
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.. 122. 2019
Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.. 121. 2019
A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.. 120. 2019
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.. 119. 2018
North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients.. 119. 2018
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.. 119. 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.. 118. 2018
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma.. 118. 2018
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.. 117. 2017
Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study.. 117. 2017
Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.. 116. 2017
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR⁺, HER2^- advanced breast cancer: results from BOLERO-2.. 116. 2017
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.. 116. 2017
Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.. 115. 2016
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.. 115. 2016
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation.. 115. 2016
Prospective changes in global DNA methylation and cancer incidence and mortality.. 115. 2016
Statin use and all-cancer survival: prospective results from the Women's Health Initiative.. 115. 2016
Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome.. 114. 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.. 114. 2016
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.. 114. 2016
Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.. 114. 2016
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.. 114. 2016
Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.. 114. 2015
Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma.. 113. 2015
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.. 113. 2015
Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers.. 113. 2015
MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project.. 113. 2015
Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.. 113. 2015
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality.. 113. 2015
Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas.. 113. 2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.. 112. 2015
Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study.. 112. 2015
Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review.. 112. 2014
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.. 111. 2014
Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma.. 111. 2014
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.. 111. 2014
Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment.. 111. 2014
Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast.. 111. 2014
Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial.. 111. 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.. 110. 2014
Breast cancer risk after radiotherapy for heritable and non-heritable retinoblastoma: a US-UK study.. 110. 2014
Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer.. 110. 2014
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.. 110. 2014
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.. 109. 2013
High-risk features in radiation-associated breast angiosarcomas.. 109. 2013
Lymph node density in oral cavity cancer: results of the International Consortium for Outcomes Research.. 109. 2013
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.. 109. 2013
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.. 109. 2013
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.. 109. 2013
IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes.. 109. 2013
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.. 108. 2013
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.. 108. 2013
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.. 108. 2013
Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.. 108. 2013
Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer.. 108. 2013
Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study.. 108. 2013
Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling.. 107. 2012
Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.. 107. 2012
Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.. 107. 2012
Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer.. 107. 2012
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.. 107. 2012
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.. 106. 2012
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.. 106. 2012
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.. 106. 2012
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.. 106. 2012
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).. 106. 2012
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.. 105. 2011
miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.. 105. 2011
Genetic architecture of prostate cancer in the Ashkenazi Jewish population.. 105. 2011
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.. 105. 2011
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.. 105. 2011
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).. 104. 2011
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma.. 104. 2011
Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study.. 104. 2010
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.. 103. 2010
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer.. 103. 2010
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.. 103. 2010
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.. 103. 2010
Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.. 102. 2010
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.. 102. 2010
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.. 102. 2010
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).. 101. 2009
Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients.. 101. 2009
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.. 101. 2009
Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa.. 101. 2009
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.. 101. 2009
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.. 100. 2009
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients.. 100. 2008
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.. 99. 2008
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer.. 99. 2008
Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.. 98. 2008
Combined modality chemoradiation in elderly oesophageal cancer patients.. 96. 2007
The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia.. 96. 2007
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.. 96. 2007
Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis.. 95. 2006
Long-term outcome among men with conservatively treated localised prostate cancer.. 95. 2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).. 94. 2006
COSMIC 2005.. 94. 2006
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.. 92. 2005
Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11.. 92. 2005
Function and quality-of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing's sarcoma: the Childhood Cancer Survivor Study.. 91. 2004
Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours.. 91. 2004
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.. 91. 2004
Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas.. 91. 2004
Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL.. 91. 2004
Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases.. 90. 2004
Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma.. 89. 2003
Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure.. 88. 2003
Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma.. 88. 2003
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.. 86. 2002
Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.. 85. 2001
hTR repressor-related gene on human chromosome 10p15.1.. 85. 2001
Genetic heterogeneity and clonal evolution in neuroblastoma.. 85. 2001
Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma.. 84. 2001
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.. 83. 2000
Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours.. 83. 2000
Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer.. 82. 2000
The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.. 82. 2000
p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy.. 82. 2000
In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour.. 81. 1999
Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cells.. 80. 1999
Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening.. 78. 1998
The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo.. 78. 1998
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.. 77. 1998
Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.. 77. 1998
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.. 77. 1998
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.. 77. 1998
A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.. 75. 1997
Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.. 74. 1996
Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.. 74. 1996
Evaluation of phenylpiperazines as targeting agents for neuroblastoma.. 74. 1996
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.. 74. 1996
Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).. 74. 1996
p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer.. 74. 1996
Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas.. 72. 1995
DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?. 72. 1995
Platinum-Taxol non-cross resistance in epithelial ovarian cancer.. 71. 1995
Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer.. 71. 1995
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.. 70. 1994
Cortisol is transported by the multidrug resistance gene product P-glycoprotein.. 67. 1993
Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates.. 66. 1992
Increased expression of differentiation markers can accompany laminin-induced attachment of small cell lung cancer cells.. 66. 1992
The effect of circulating antigen and radiolabel stability on the biodistribution of an indium labelled antibody.. 64. 1991
The distribution of alternative agents for targeted radiotherapy within human neuroblastoma spheroids.. 63. 1991
Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: relevance to microdosimetry.. 61. 1990
Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2.. 60. 1989
Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.. 59. 1989
Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.. 56. 1987
Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model.. 51. 1985
Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells.. 50. 1984
Retinoma: spontaneous regression of retinoblastoma or benign manifestation of the mutation?. 45. 1982
NMR in cancer, XIII: application of the NMR malignancy index to human mammary tumours.. 38. 1978
Nuclear magnetic resonance in cancer, XII: Application of NMR malignancy index to human lung tumours.. 36. 1977
Correction: Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.. 126. 2022
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells. 2021
Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. 2016
Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. 2014
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC).. 119. 2018
Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma.. 119. 2018
Promoting exercise after a cancer diagnosis: easier said than done.. 110. 2014
"Stromal cells in prostate cancer pathobiology: friends or foes?". 2022
Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'? 2022
Targeting obesity-related dysfunction in hormonally driven cancers. 2021
Cancer metastasis as a non-healing wound. 2021
Cancer health disparities in racial/ethnic minorities in the United States. 2020
Reprogramming of fatty acid metabolism in cancer. 2019
Genome-wide association study of germline variants and breast cancer-specific mortality. 2019
Comparing comparators: a look at control arms in kidney cancer studies over the years. 2014
The AURORA initiative for metastatic breast cancer. 2014
Immune modulation for cancer therapy. 2014
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. 2014
A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. 2010
Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. 2008
Targeted therapy for metastatic renal cell carcinoma. 2006
Genomic approaches in the management and treatment of breast cancer. 2005
A note on competing risks in survival data analysis. 2004
Radioimmunotherapy of malignancy using antibody targeted radionuclides. 1986

VIVO Weill Cornell Medical College

British journal of cancer Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)